A cute myocarditis (AM) is generally caused by a postviral immune response, even if other triggers such as drug hypersensitivity reactions, infections, immune checkpoint inhibitors, or systemic autoimmune disorders have been involved. [1] [2] [3] [4] [5] Postmortem examinations in young adults have demonstrated that AM was responsible for 3% to 12% of cases of sudden cardiac death. [6] [7] [8] In contrast, in-hospital and long-term outcomes of patients admitted with clinically suspected AM remain undetermined. So far, most large studies on AM were carried out in tertiary referral hospitals, were monocentric, and included between 100 and 200 patients, [9] [10] [11] [12] with variable timing of diagnosis from symptom onset.
There is evidence that the prognosis of patients with AM can be predicted, at least in part, on the basis of the clinical presentation. Patients presenting with ventricular arrhythmias (VAs) or symptoms of heart failure have worse prognosis compared with those presenting with chest pain. [11] [12] [13] [14] [15] Accordingly, in the United States, there is consensus that an endomyocardial biopsy (EMB) should be performed primarily in those cases with VA and conduction abnormalities or advanced heart failure of recent onset (ie, within 1 month of symptom onset) to exclude eosinophilic and giant cell myocarditis or cardiac sarcoidosis, which have worse outcomes and benefit from immune suppression. 1, 16, 17 In contrast, European experts recommend performing EMB in all cases of clinically suspected AM. 18 However, in the real world, the perceived usefulness of EBM in the setting of AM is relatively low. Overall, in the United States between 2002 and 2014, ≈1 EMB in a native heart per 1 million patients was performed, and in 2014, only 8% of these were carried out in clinically suspected AM. 19 Two recent multicenter studies in >1000 patients 20, 21 have proved the incremental diagnostic role of cardiac magnetic resonance (CMR) in patients with suspected AM, confirming previous studies showing that the presence, location, and extent of late gadolinium enhancement (LGE) allow the detection and quantification of myocardial damage, as well as the prediction of patient outcome. 15, 16, 22, 23 Finally, although there is preliminary evidence that in young children (1-6 years old) AM can be followed by dilated cardiomyopathy, it is still debated whether adult patients with AM are at higher risk of developing dilated cardiomyopathy during follow-up. 1, 24 In this retrospective multicenter study of 443 patients with AM, our aim was to define the natural history of the condition from the time of its diagnosis up to a median follow-up of 35 months. We studied patients without concurrent cardiac disorder and with symptom onset within 1 month. The diagnosis of AM was confirmed either by EMB or by the combination of positive necrosis biomarkers and CMR criteria. Compared with our previous report on patients with AM presenting with fulminant versus nonfulminant forms admitted to 2 referral hospitals, 14 the present study is based on a multicenter registry. We enrolled symptomatic patients with a diagnosis of AM based on either histology or increased troponin plus edema and LGE on CMR. Here, we evaluated beyond cardiac mortality and need for heart transplantation (HTx), major events related to AM, and in approximately half of cases the changes in volumes and left ventricular (LV) ejection fraction (EF) on CMR. Thus, the present study illustrates the clinical characteristics, in-hospital management, and long-term outcome of a contemporary cohort of patients with AM.
METHODS
The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure because the current ethics approval does not allow us to share sensitive patient data with other researchers without local Institutional Review Board approval.
Clinical Perspective
What Is New?
• Patients with uncomplicated acute myocarditis have benign short-and long-term outcomes, although all patients in our series have evidence of increased necrosis biomarkers and late gadolinium enhancement at cardiac magnetic resonance.
• When left ventricular ejection fraction at first cardiac magnetic resonance is preserved, the risk of developing an inflammatory cardiomyopathy at the midterm follow-up is very low.
• Autoimmune or systemic inflammatory disorders must be investigated in patients with acute myocarditis because an autoimmune disorder can be found in 7.2% of patients admitted, particularly in those with complicated presentation (15.4%).
What Are the Clinical Implications?
• Patients can be effectively stratified on the basis of their initial clinical presentation: patients with left ventricular ejection fraction <50% at first echocardiogram, those with sustained ventricular arrhythmias, and those with low cardiac output syndrome (called complicated acute myocarditis) are at higher risk of cardiac events compared with those without the above manifestations (uncomplicated cases), who are at lower risk.
• Our overall approach may help identify the most effective allocation of available resources and, in particular, does not support the idea that performing an endomyocardial biopsy can improve prognosis, at least in patients with uncomplicated acute myocarditis.
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Study Population and Diagnosis of Myocarditis
Patients admitted to 19 hospitals with catheterization laboratories and CMR facilities in Lombardy, a northern Italian region with a population exceeding 10 million, from May 2001 to February 2017 with clinically suspected AM were retrospectively screened and their data centrally revised on prespecified criteria for final inclusion in the data set. The Niguarda Hospital in Milan was the coordinating center. The appropriate ethics committee (Milano Area C) approved the study (identifier 120-032016), and data were collected in accordance with the Institutional Review Board. All the hospitals were at a maximal distance of 100 km (62 miles) from the coordinating center with a homogeneous population and similar standards of care. The full list of centers is reported in the Appendix in the online-only Data Supplement.
Patients were locally identified through the International Classification of Diseases, Ninth Revision diagnostic codes (422.0, 422.91, 422.92, 422.93, 422.99, 429.89) recorded in hospital discharge forms or through the hospital lists of cases diagnosed with AM by histology or CMR and confirmed by revision of clinical records. The local hospitals were asked to consider only those patients with onset of cardiovascular symptoms within 30 days before admission. Patients with a previous or current diagnosis of ischemic heart disease or an alternative diagnosis at discharge were excluded. Per protocol, only patients with histologically proven myocarditis (from EMB, explanted heart, or postmortem examination) or with positive necrosis biomarkers (troponins or creatine kinase-MB) combined with 2 CMR criteria for AM (edema on the darkblood T2-weighted short tau inversion recovery sequence and LGE) and with nonischemic pattern of LGE were included. It has previously been demonstrated that the coexistence of these 2 "Lake Louise" CMR criteria has a specificity of 91% for the diagnosis of AM compared with histology. 22 In addition, all patients included in the analysis had no evidence of coronary artery disease (patients >50 years of age without available coronary angiography were excluded). Furthermore, patients >70 years of age were excluded because potential confounders could not be completely ruled out by CMR (ie, takotsubo or other conditions associated with the aging heart). Among the 684 identified patients, 443 (64.8%) fulfilling the prespecified criteria were included in the final analysis ( Figure 1 and Table I in the online-only Data Supplement). Myocardial histology was available in 61 of 443 patients (13.7%; EMB in 56 cases, postmortem examination in 4 cases, and explanted heart in 1 case). The last data on followup were acquired in July 2017. A subset of patients enrolled in the present study (170 of 443, 38.4%) from the Niguarda Hospital in Milan and San Matteo Hospital in Pavia were also included in our previous report.
14
End Points
The main study end point was the overall incidence of cardiac death and HTx. Secondary study end points were all-cause deaths and HTx and a composite of major AM-related cardiac events that occurred after the acute phase. The latter combined end point included cardiac death and HTx (excluding in-hospital events), sustained VAs treated with electric shock or ablation, and symptomatic heart failure needing device implantation. In the patients with follow-up CMR, the prevalence of reduced LVEF and evidence of LV dilation (considering the threshold of indexed LV end-diastolic volume [ 
RESULTS
The main characteristics of the study population are reported in Table 1 . Median age at presentation was 34 years, and 19.4% of the patients were female. The most frequent symptom at presentation was chest pain (86.7% of patients), followed by dyspnea (19.2%); 80.5% of patients had prodromal symptoms. An associated autoimmune disorder was observed in up to 7.2% of patients. Eosinophilic granulomatosis with polyangiitis and mixed connective tissue disease were the most frequently observed autoimmune or systemic inflammatory disorders ( Table 2) .
The 443 patients were subdivided into 2 groups based on the clinical presentation at the time of hospital admission. Group 1 (complicated AM) included 118 patients (26.6%) with AM complicated by LV systolic dysfunction (ie, LVEF <50% on the first in-hospital echocardiogram), with documented sustained VAs, or with a fulminant presentation (ie, low cardiac output syndrome requiring inotropes or mechanical circulatory support). 15, 16 Group 2 (uncomplicated AM) included the remaining 325 patients (73.4%). Follow-up was completed in all but 5 patients (1.1%), who were lost after discharge (2 non-European citizens and 3 Italian citizens not resident in Lombardy). Median follow-up was 35 months (interquartile range [Q1-Q3], 15-59 months) with a maximum follow-up of 188 months. The median length of follow-up did not differ between the 2 groups (P=0.38).
Women were more prevalent in the group with complicated AM. Symptoms of heart failure were more frequent in patients with complicated AM who had lower LVEF on the first echocardiogram compared with patients with uncomplicated AM.
Right ventricular EMB was performed in 56 of 443 patients (12.6%). EMB was performed in 47 of 118 patients (39.8%) with complicated AM compared with 9 of 325 patients (2.8%) with uncomplicated AM. Histological evidence of active myocarditis, based on Dallas criteria, 27 was observed in 50 of the 56 EMBs (89.3%). The most common histological subtype was lymphocytic myocarditis in both complicated and uncomplicated AM (67.3% and 66.7%, respectively; Table II in the online-only Data Supplement).
Baseline CMR was performed in 415 of the 443 patients (93.7%) and was acquired earlier in patients with uncomplicated AM (median delay from hospitalization, 4 days; Q1-Q3, 3-7 days) compared with those with complicated AM (6 days; Q1-Q3, 3-15 days; P=0.006; Table II in the online-only Data Supplement). As per protocol, all 415 patients scanned had evidence of myocardial edema and LGE.
Treatment differed substantially in the 2 groups (Table III in the online-only Data Supplement). Immunosuppressive agents, in particular intravenous steroids, were used in up to 37.2% of patients presenting with complicated AM compared with 2.8% of those with uncomplicated presentation (P<0.0001). Nonsteroidal anti-inflammatory drugs were used more frequently in patients with uncomplicated presentation than in those with complicated presentation (67.6% versus 44%; P<0.0001). β-Adrenoceptor blockers were used frequently in both groups (61.9% in complicated versus 53.8% in uncomplicated forms; P=0.18), whereas angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers were used more frequently in patients with complicated AM (72.4% versus 49.1%; P<0.0001).
Clinical Outcome
In-hospital mortality and HTx in the whole study population (n=443) was 3.2% (10 cardiac deaths and 4 HTx), and these events occurred exclusively in patients with complicated AM. Furthermore, a venous-arterial extracorporeal membrane oxygenation or a ventricular assist device was used in 23 of 443 patients (5.2%), all with complicated AM. Estimated cardiac mortality and HTx at 1, 3, and 5 years of follow-up were 3.0%, 3.3%, and 4.1%, respectively ( Figure 2A ). As shown in Figure 2B , cardiac mortality and HTx rates at 1, 3, and 5 years of follow-up were 11.3%, 12.5%, and 14.7%, respectively, in the group with complicated AM compared with 0% in those with uncomplicated AM (logrank P<0.0001). Death resulting from all causes and HTx rate in the whole population at 5 years was 5.2%, with a higher incidence in complicated versus uncomplicated cases (18.0% versus 0.3%, respectively; logrank P<0.0001; Figure I in the online-only Data Supplement). Major AM-related cardiac events after the acute 
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phase occurred in 2.8% at the 5-year follow-up, with a significantly higher incidence in patients with complicated AM (10.8% versus 0% in uncomplicated AM; log-rank P<0.0001; Figure 3 and Table 3 ). In the group with complicated AM, there was a slight improvement in LVEF at follow-up, whereas the LVEF at follow-up was unchanged in uncomplicated AM ( Figure 4A and 4B). The proportion of patients with reduced LVEF on AM indicates acute myocarditis; AV, atrioventricular; CAD, coronary artery disease; CK-MB, creatine kinase isoenzyme MB; CRP, C-reactive protein; CT, computed tomography; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; Q1-Q3, first through third quartile; and RV-TAPSE, right ventricular tricuspid annular plate systolic excursion.
Changes in LV Function at Follow-Up
*Fulminant presentation indicates patients with low cardiac output syndrome requiring inotropes or mechanical circulatory support. †See Table 2 for details on associated autoimmune disorders.
follow-up CMR was larger among patients with complicated AM compared with those with uncomplicated AM ( Figure 4C ). At follow-up, only 1 of 145 patients (0.7%) with uncomplicated AM had an LVEF <50% compared with 8 of 55 (14.5%) of those with complicated AM. Similar results were obtained when indexed LVEDV was considered (n=190). A larger proportion of patients with complicated AM had LV enlargement at follow-up compared with those with uncomplicated AM (17.3% versus 2.9%; relative risk, 1.17; 95% confidence interval, 1.03-1.33; P=0.003; Figure II in the online-only Data Supplement). 
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Figure 2. Kaplan-Meier estimates of 5-year cardiac mortality and heart transplantation (HTx).
A, Events in the whole study population with acute myocarditis (AM) and (B) events in patients with AM complicated at presentation by left ventricular ejection fraction <50%, sustained ventricular arrhythmias (VAs), or a low cardiac output syndrome compared with patients without such complications at presentation. Of total cardiac deaths and HTx, 16 patients initially presented with fulminant presentation and 1 with VAs. One cardiac death occurred after HTx and was omitted.
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DISCUSSION
The main finding of the present multicenter study in patients with AM is that cardiac death and HTx occurred in 3.2% of patients during hospitalization and in 4.1% of patients at the 5-year follow-up. Although these figures are relatively low compared with previous reports, 9, 12, 15, 28 we believe that they are a more realistic reflection of the short-and long-term outcomes of patients with AM currently admitted to hospitals. As supporting independent data, a Finnish study on childhood myocarditis also demonstrated a relatively low occurrence of in-hospital death and HTx (1.9%) among all children admitted with AM. 29 Differences in patient cohorts and study design may explain, at least in part, the discrepancies with previous studies, which generally included smaller numbers of patients and used nonuniform criteria for diagnosing AM. Some reports included only patients with histologically proven AM, whereas others enrolled cases of suspected AM selected only on the basis of CMR criteria. These differences might have affected the estimation of adverse events in the short and long term. 30 The incon- A, Events in the overall population of patients with AM and (B) events in patients with AM complicated at presentation by left ventricular ejection fraction (LVEF) <50%, sustained ventricular arrhythmias (VAs), or a low cardiac output syndrome compared with patients with uncomplicated AM at presentation. The composite of major AM-related cardiac events that occurred after the acute phase included cardiac death and heart transplantation (excluding in-hospital events), sustained VAs treated with electric shock or ablation, and symptomatic heart failure needing device implantation. Three patients who died during follow-up initially had a fulminant presentation; 2 patients who were transplanted during follow-up initially had a fulminant presentation; 2 patients who had a sustained ventricular arrhythmias treated with shock or ablation in the follow-up initially had a sustained ventricular arrhythmias and 2 patients had a fulminant presentation; and 1 patient who was implanted with a cardiac resynchronization therapy device because of symptomatic heart failure during follow-up initially had an LVEF <50%. HTx indicates heart transplantation.
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Figure 4. Changes in left ventricular (LV) ejection fraction (EF) between baseline and follow-up (median time, 196 days) cardiac magnetic resonance (CMR).
A, Patients with complicated acute myocarditis (AM) at presentation had a significant improvement in LV systolic function. B, Patients with uncomplicated AM had a similar LVEF at follow-up (Wilcoxon matched-pair signed-rank test was used for comparisons). C, Proportion of patients with an LVEF <55%, considering that a threshold for impaired LV systolic function on CMR was higher among patients with complicated AM. Nevertheless, it must be noted that in the last decade, the diagnosis of AM has been made more frequently as a result of the introduction of sensitive troponins and CMR imaging. This might have increased the relative proportion of uncomplicated AM in our population, resulting in a better outcome compared with older studies in which the diagnosis was based mainly on histology.
The second relevant result of our study is that cardiac mortality and HTx in both the short (in-hospital, 11.9%) and long (18.0% at the 5-year follow-up) term occurred exclusively in patients with complicated AM, presenting at admission with LVEF <50% on the first echocardiogram, sustained VAs, or hemodynamic instability. Patients with uncomplicated AM had more benign short-and long-term outcomes, although all patients had evidence of increased necrosis biomarkers and LGE on CMR. It must be noted that most of the unfavorable events took place during the initial hospitalization. Furthermore, 14.5% of the patients with complicated AM had evidence of impaired LV function (ie, LVEF <50%) on the follow-up CMR. In line with this, evidence of progressive LV dilation at follow-up was found in 17.3% of the patients with complicated AM compared with only 2.9% of those with uncomplicated AM. In the uncomplicated group, only 1 patient with preserved LVEF at baseline CMR had a LVEF <50% at follow-up. This patient, despite uncomplicated presentation and LVEF >55% on the baseline CMR, had peripheral eosinophilia, which led to an EMB demonstrating an eosinophilic myocarditis. Peripheral eosinophilia in the scenario of a clinically suspected AM represents a Class 2A indication for EMB. 17, 18 One important message that can be derived from the present study is that patients can be effectively stratified on the basis of their initial clinical presentation, main vital signs, and instrumental findings (ECG and echocardiography; Figure 5 and Figure III in the online-only Data Supplement).
Another significant difference compared with previous studies is that the median LV end-diastolic diameter was in the normal range (49 mm, including those with complicated AM, in whom it was 50 mm) on the first echocardiogram, thus confirming recent onset of the inflammatory damage, without evidence of remodeling. The largest monocentric report on myocarditis (n=670) published so far bears several important differences compared with our study. The diagnosis of myocarditis was based on CMR imaging; 38% of the cases included were outpatients 20 ; 48% of the patients had symptom AM indicates acute myocarditis; CRT, cardiac resynchronization therapy; HTx, heart transplantation; ICD, implantable cardiac defibrillator; STEMI, STsegment-elevation myocardial infarction; SVT, sustained ventricular tachycardia; VAD, ventricular assist device; and Va-ECMO, venoarterial extracorporeal membrane oxygenation.
*One patient died after HTx as a result of severe graft rejections and graft dysfunction (initial diagnosis, giant cell myocarditis). †Noncardiac deaths were caused by suicide in 2 patients, cancer in 1 patient, and infection in another patient in the complicated AM group and by cancer in 1 patient in the uncomplicated AM group.
‡The patient was initially admitted for a syncope and diagnosed with a suspected AM. During follow-up, an ambulatory electrocardiographic monitoring demonstrated a nonsustained asymptomatic ventricular arrhythmia; thus, he was implanted. No ventricular arrhythmias were further recorded after ICD implantation.
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onset >2 weeks previously; and the median LVEDV was 189 mL (indexed LVEDV >98 mL/m 2 ). Thus, almost half of the patients had LV dilation at the time of evaluation, suggesting an inflammatory damage of longer duration compared with the patients included in our study. Furthermore, the median transplantation-free survival at 5 years was 95.7%, and the main predictors of outcome were age (patients were older compared with our study, ie, 48 versus 34 years), presence of LGE (all patients in our study had evidence of LGE, so it could not be considered a potential predictor, but this increased the specificity of the diagnosis of AM in our study), and LVEF <40%. It should be noted that in our study, the presence of reduced LVEF was a predictor of high risk at follow-up.
EMB was performed in 12.6% of the patients, primarily in those with complicated AM. This is in line with the current indications of the American Heart Association and American College of Cardiology. 16, 18 Our results demonstrate that the decision not to perform an EMB in uncomplicated patients at admission is not associated with an increased risk of complications in both the short and long term. Our findings do not support the idea that performing an EMB can improve the prognosis of patients with uncomplicated AM. 4 On the other hand, our results support the use of CMR both for the diagnosis of AM and for patient stratification. Overall, our patients demonstrated relatively small changes in LVEF between the baseline CMR, performed during hospitalization or early after discharge, and the second CMR scan, performed after ≈200 days from the initial admission. It has previously been observed that most changes in LVEF in patients with fulminant presentation and severe LV dysfunction take place in the first 2 weeks after admission.
14 In these patients, CMR is generally delayed because of hemodynamic instability.
14 A transition from AM to dilated cardiomyopathy mediated by viral persistence in the myocardium has been suggested in murine models. 1 The stable/improved indexed LVEDV found in most of our patients at follow-up does not lend support to the hypothesis of ) at hospital admission can effectively identify patients at risk of death, heart transplantation (HTx), and long-term ventricular assist device (LT-VAD) during hospitalization (increased-risk AM group). Further information on reduced LVEF (<55%) on the baseline cardiac magnetic resonance (CMR) associated with the initial clinical presentation can effectively identify those patients at risk of further major AM-related cardiac events (composite of cardiac death, HTx, sustained VAs treated with electric shock or ablation, and symptomatic heart failure needing device implantation) during follow-up or those at risk of having a reduced LVEF on a follow-up CMR. In particular, the prognosis in term of events and risk of LVEF impairment is minimal in patients with uncomplicated AM at presentation and LVEF ≥55% on the baseline CMR (low-risk AM group). The proportion of AM-related events was significantly higher in the high-risk group compared with the low-risk group (9.5% vs 0%; P=0.0008, Fisher exact test). Similarly, the proportion of patients with LVEF <55% at follow-up was significantly higher in the high-risk group compared with the low-risk group: 21.6% vs 3.9% (relative risk for LVEF <55% at follow-up, 5.49; 95% confidence interval, 2.10-14.4; P=0.0002). BP indicates blood pressure. *The number of patients included in the follow-up after discharge was the sum of those with a baseline and a follow-up CMR (n=200) plus 1 patient (with complicated presentation) who had a baseline CMR and had an event in the follow-up that prevented the patient from undergoing the follow-up CMR.
progressive LV remodeling late after the acute episode in the absence of persistent or recurrent injury.
The present study has pointed out that autoimmune disorders must be investigated; they were found in 7.2% of all patients with AM, particularly in those with complicated presentation (15.4%). Therefore, those patients who have associated autoimmune or systemic inflammatory disorders (such as cardiac sarcoidosis or eosinophilic granulomatosis with polyangiitis) must be followed up and considered at risk of further events and potential evolution to inflammatory cardiomyopathy. 1, 16 In line with this, there is evidence that pharmacological blocking of multiple immune checkpoints by immunotherapy used against cancer (cytotoxic T-lymphocyte-associated antigen 4 by ipilimumab and programmed death-1 by nivolumab) can lead to fulminant AM, suggesting a key role of immune response in the onset of AM. 5 In the setting of AM and in particular in patients with complicated presentation, the use of immunosuppressive agents such as steroids must be further investigated.
Most of the previous studies tested the use of immunosuppressive agents in patients with inflammatory cardiomyopathy during the chronic phase. [32] [33] [34] [35] In addition, in the MTT, <45% of patients were randomized to immunosuppression within 1 month of symptom onset. 28 In our multicenter experience, physicians still use steroids in AM (11.4%), especially in patients with complicated AM (37.2% versus 2.8% in uncomplicated AM). The current use of immunosuppressive agents is reduced compared with previous series, before the MTT, in which physicians used immunosuppressive agents in up to 63% of cases. 36 Nonsteroidal anti-inflammatory drugs were frequently used without increased risk, particularly in uncomplicated AM at presentation (in 67.6%). This finding does not support the evidence that nonsteroidal anti-inflammatory drugs worsen the prognosis of viral myocarditis as observed in murine models. 37 β-Blockers, which have been suggested to be protective in patients with myocarditis, 12 were the most frequently used drug in our patients with AM (up to 55.8%), without significant differences between uncomplicated and complicated AM at presentation. Most drugs prescribed in uncomplicated AM are not evidence-based, in particular the diffuse use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (in 49.1%). These results underscore the need for clinical trials to demonstrate the efficacy of these drugs in the setting of AM, in particular in those with the presence of LGE. 20, 21 Finally, this registry confirms that AM occurs more frequently in male subjects (≈80%), 38 although women more frequently have complicated AM and are therefore at higher risk of complications. The male prevalence observed in our population is consistent with data from the nationwide Finnish study (n=213) that included children hospitalized for AM. Those investigators observed that the prevalence of male sex increased with age, and in children 11 to 15 years of age, the prevalence of male sex was 80%. 29 Another study focusing on the outcome of patients with pericarditis reported that the prevalence of male sex was ≈80% in those with myocarditis associated with pericarditis (myopericarditis or perimyocarditis) compared with individuals with isolated pericarditis, in whom the prevalence of male sex dropped to 54%. 39 Similarly, in 2 other studies of AM diagnosed by CMR with a median LVEF >55%, the prevalence of male sex was 77% and 76%. 21, 31 The prevalence of male sex can decrease on the basis of the inclusion of high-risk patients, as observed in previous studies in which the diagnosis was driven mainly by EMB and the mean LVEF was ≈40% with a male prevalence of ≈60%.
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Study Limitations
The retrospective nature of this registry may have introduced potential bias. Because the registry spans a 16-year period, the availability of CMR and even EMB could have changed. Nevertheless, we believe that our population reflects the real-world practice more realistically, particularly in regard to the outcome of AM, compared with the previous monocentric experience of patients with EMB. Furthermore, the clinical practice of our 19 hospitals in Lombardy may not be reflected elsewhere in Europe or the United States, particularly in terms of the relatively high use of steroids and antiremodeling medications. We cannot exclude that this approach could have affected the reported more favorable prognosis. Nevertheless, this point stresses again the need for randomized clinical trials to assess drugs able to reduce the mortality rate in this particular setting of young individuals. Moreover, even though 19 centers participated in this registry, their relative contributions were significantly different, as reported in Table I in the online-only Data Supplement. Finally, there was no centralized review of pathology and CMR data in this registry. It must be noted that even if there was no core facility for the CMR images, the identification of areas with positive short tau inversion recovery or LGE and the calculation of volumes of the LV and LVEF with CMR have high accuracy and interobserver reproducibility. 25 The absence of a core echocardiography laboratory and the impossibility of retrieving several original echocardiographic images were the reasons we did not report changes in LVEF at follow-up based on echocardiography.
CONCLUSIONS
Our study points out that most cardiac deaths and HTx after AM occur during the initial hospitalization. We show that integration of clinical data, necrosis biomarkers, CMR, and EMB, when indicated, can effectively identify patients at increased risk of major adverse
